Growth Hormone
CJC-1295 (no-DAC)
A growth-hormone-releasing-hormone analog researched for its ability to stimulate endogenous pulsatile GH secretion, often paired with a GHRP.
Also known as: Mod GRF 1-29
Quick facts
Molecular weight
3,367 Da
Half-life
0.5 h
Frequency
daily
Admins / wk
7
Routes
SubQ
Typical dose
100 mcg–200 mcg
Mechanism & positioning
A growth-hormone-releasing-hormone analog researched for its ability to stimulate endogenous pulsatile GH secretion, often paired with a GHRP.
Researched for: GHRH analog action, pulsatile GH release.
Reconstitution defaults
Default vial
2 mg
BAC water
2 mL
Concentration
1000 mcg/mL
Doses per vial
~20
Other stocked vial sizes: 5 mg.
Calculate with this peptide
Documented pairwise interactions
- warning
CJC-1295 (no-DAC) + CJC-1295 (with DAC)
Short-acting and long-acting forms of the same GHRH analog; combining the two stacks receptor stimulation without literature support.
- caution
CJC-1295 (no-DAC) + Ipamorelin
Common research pairing (GHRH + GHRP); monitor for synergistic GH/IGF-1 elevation.
- warning
CJC-1295 (no-DAC) + Tesamorelin
Both are GHRH analogs targeting the same receptor; combination provides no additive benefit and may downregulate receptor sensitivity.
- warning
CJC-1295 (no-DAC) + Sermorelin
Two GHRH 1-29 analogs at the same receptor; combination provides no additive benefit.
References
- Teichman SL et al., J Clin Endocrinol Metab, 2006.
Related peptides in the Growth Hormone class
CJC-1295 (with DAC)
CJC-1295 conjugated to a Drug Affinity Complex linker that binds serum albumin, extending half-life to roughly eight days and producing a steady GHRH-axis baseline rather than pulsatile peaks.
Ipamorelin
A selective ghrelin-mimetic pentapeptide investigated for triggering GH release with minimal off-target hormonal effects.
Tesamorelin
A stabilised GHRH analog researched extensively in HIV-associated lipodystrophy for its visceral-fat-reducing properties.
Sermorelin
The original 1-29 amino-acid fragment of GHRH; researched for restoring pulsatile growth-hormone secretion via direct hypothalamic-pituitary axis stimulation.
Hexarelin
A six-amino-acid growth-hormone-releasing peptide investigated for potent acute GH release and ancillary cardiovascular research models.
IGF1-LR3
A long-acting IGF-1 analog with an extended N-terminal sequence and an arginine substitution that reduces IGF-binding-protein affinity, producing a substantially longer circulating half-life than native IGF-1.